About EirGenix
About EirGenix
Milestones
Vision and Mission
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP manufacturing–mammalian system
cGMP manufacturing–microbial system
Antibody-Drug Conjugate
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
CRM197 CARRIER PROTEIN
PRODUCT PIPELINE
COVID-19 ANTIGEN RAPID TEST
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2025
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Shareholders' Information
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
0
Inquiry
EN
繁中
Contact us
0
Inquiry
About EirGenix
About EirGenix
Milestones
Vision and Mission
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP manufacturing–mammalian system
cGMP manufacturing–microbial system
Antibody-Drug Conjugate
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
CRM197 CARRIER PROTEIN
PRODUCT PIPELINE
COVID-19 ANTIGEN RAPID TEST
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2025
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Shareholders' Information
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
Search
×
Submit
×
Home
首頁用資料
區塊2
1000
1000
Annual production of antibodies can reach up to 1,000kg
1000
Back to the previous page
